MORARI, Michele
 Distribuzione geografica
Continente #
NA - Nord America 1.103
EU - Europa 718
AS - Asia 318
OC - Oceania 12
AF - Africa 11
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 3
Totale 2.175
Nazione #
US - Stati Uniti d'America 1.070
IT - Italia 187
CN - Cina 140
FR - Francia 106
CH - Svizzera 82
DE - Germania 52
GB - Regno Unito 52
JP - Giappone 50
FI - Finlandia 38
SE - Svezia 37
NL - Olanda 34
UA - Ucraina 25
CA - Canada 24
HK - Hong Kong 21
IN - India 19
BE - Belgio 17
PL - Polonia 16
ES - Italia 15
VN - Vietnam 12
CZ - Repubblica Ceca 11
KR - Corea 11
SG - Singapore 11
AE - Emirati Arabi Uniti 10
AU - Australia 10
TW - Taiwan 10
BR - Brasile 9
IE - Irlanda 9
RU - Federazione Russa 9
MX - Messico 8
IR - Iran 6
LU - Lussemburgo 5
MA - Marocco 5
TH - Thailandia 5
EG - Egitto 4
KZ - Kazakistan 4
NO - Norvegia 4
PH - Filippine 4
TR - Turchia 4
GR - Grecia 3
ID - Indonesia 3
MK - Macedonia 3
MO - Macao, regione amministrativa speciale della Cina 3
RO - Romania 3
RS - Serbia 3
AL - Albania 2
EU - Europa 2
NZ - Nuova Zelanda 2
QA - Qatar 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
IL - Israele 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
PE - Perù 1
PT - Portogallo 1
SI - Slovenia 1
TT - Trinidad e Tobago 1
UG - Uganda 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 2.175
Città #
Ashburn 192
Santa Cruz 110
Columbus 87
Ferrara 81
Lausanne 48
Fairfield 45
Houston 38
Seattle 33
Shanghai 26
Des Moines 24
Lappeenranta 24
Stockholm 23
Chicago 22
Ann Arbor 18
Buffalo 18
Amsterdam 17
Woodbridge 16
San Diego 15
Tokyo 15
Warsaw 15
Cambridge 14
Helsinki 14
Wilmington 14
Dong Ket 12
Los Angeles 12
New York 12
Atlanta 11
Boardman 11
Leuven 11
Toronto 11
Chongqing 10
Council Bluffs 10
Paris 10
Dublin 9
Madison 9
Écublens 9
Beijing 8
Milan 8
Lake Forest 7
Modena 7
Neuchatel 7
San Jose 7
Tappahannock 7
Bengaluru 6
Bridgend 6
Dallas 6
Ferrara di Monte Baldo 6
Hangzhou 6
London 6
Philadelphia 6
Sapporo 6
Birmingham 5
Clearwater 5
Fremont 5
Guangzhou 5
Las Vegas 5
Nanjing 5
Oxford 5
Berlin 4
Central 4
Geneva 4
Gothenburg 4
Herndon 4
Kansas City 4
Kolkata 4
Montreal 4
Nottingham 4
Rabat 4
Rome 4
Saint-Prex 4
San Francisco 4
Seoul 4
Taipei 4
Varedo 4
Bangkok 3
Belgrade 3
Bilbao 3
Brisbane 3
Calgary 3
Cologne 3
Fuzhou 3
Grenoble 3
Hamburg 3
Henderson 3
Lexington 3
Macao 3
Naples 3
Nashville 3
Nishitawara 3
Padova 3
Randaberg 3
Recife 3
Riva 3
Shymkent 3
Skopje 3
Sunnyvale 3
Târgu Mureş 3
Umeda 3
Villaz-Saint-Pierre 3
Xian 3
Totale 1.322
Nome #
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease, file e309ade3-dd88-3969-e053-3a05fe0a2c94 334
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice, file e309ade1-ed74-3969-e053-3a05fe0a2c94 290
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release, file e309ade0-9bcd-3969-e053-3a05fe0a2c94 144
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease, file e309ade3-db82-3969-e053-3a05fe0a2c94 115
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists, file e309ade3-f974-3969-e053-3a05fe0a2c94 100
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease, file 097ccc8a-9bab-450f-9e98-c5824f903d52 89
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists, file e309ade1-b603-3969-e053-3a05fe0a2c94 80
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice, file e309ade1-5825-3969-e053-3a05fe0a2c94 78
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors, file e309ade0-9cc5-3969-e053-3a05fe0a2c94 68
Role of LRRK2 in the regulation of dopamine receptor trafficking, file e309ade1-a6c4-3969-e053-3a05fe0a2c94 63
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia, file e309ade1-acb4-3969-e053-3a05fe0a2c94 62
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling, file e309ade2-701e-3969-e053-3a05fe0a2c94 59
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models, file e309ade2-a3ae-3969-e053-3a05fe0a2c94 54
L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter, file e309ade5-0769-3969-e053-3a05fe0a2c94 53
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain, file e309ade0-a22b-3969-e053-3a05fe0a2c94 51
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease, file e309ade1-0e3d-3969-e053-3a05fe0a2c94 49
Autophagy and LRRK2 in the Aging Brain, file e309ade2-7416-3969-e053-3a05fe0a2c94 47
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease, file e309ade1-a23e-3969-e053-3a05fe0a2c94 44
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes, file e309ade2-5f1e-3969-e053-3a05fe0a2c94 42
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia, file e309ade5-0042-3969-e053-3a05fe0a2c94 37
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4, file e309ade1-f664-3969-e053-3a05fe0a2c94 34
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity, file e309ade3-fe3e-3969-e053-3a05fe0a2c94 34
Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice, file e309ade5-7160-3969-e053-3a05fe0a2c94 19
Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance, file e309ade4-d80f-3969-e053-3a05fe0a2c94 16
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates, file e309ade2-a346-3969-e053-3a05fe0a2c94 14
Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation, file e309ade2-a37c-3969-e053-3a05fe0a2c94 14
Managing Parkinson's disease: moving ON with NOP, file e309ade2-7490-3969-e053-3a05fe0a2c94 13
Early dysfunction of substantia nigra dopamine neurons in the parkinq311x mouse, file e309ade4-f037-3969-e053-3a05fe0a2c94 13
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata, file e309ade4-f031-3969-e053-3a05fe0a2c94 12
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia, file ed9f748f-2295-43dd-958c-1fca8b754276 12
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia, file e309ade0-a123-3969-e053-3a05fe0a2c94 11
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity, file e309ade1-5207-3969-e053-3a05fe0a2c94 11
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity, file e309ade5-310c-3969-e053-3a05fe0a2c94 11
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats, file e309ade3-287f-3969-e053-3a05fe0a2c94 10
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging, file e309ade0-460c-3969-e053-3a05fe0a2c94 9
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia, file e309ade5-0987-3969-e053-3a05fe0a2c94 8
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives, file e309ade2-5f84-3969-e053-3a05fe0a2c94 7
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity, file e309ade3-2885-3969-e053-3a05fe0a2c94 6
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology, file 660767c4-c52f-4353-8780-a91df8f457d4 5
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands, file e309ade0-4197-3969-e053-3a05fe0a2c94 5
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex, file e309ade0-ca5e-3969-e053-3a05fe0a2c94 5
Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo, file e309ade5-076b-3969-e053-3a05fe0a2c94 5
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease, file e309ade0-9fb4-3969-e053-3a05fe0a2c94 4
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors, file e309ade4-0894-3969-e053-3a05fe0a2c94 4
null, file e309ade0-2862-3969-e053-3a05fe0a2c94 3
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity, file e309ade0-341d-3969-e053-3a05fe0a2c94 3
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity, file e309ade0-a262-3969-e053-3a05fe0a2c94 3
LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation, file e309ade5-3c64-3969-e053-3a05fe0a2c94 3
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway, file e309ade0-224b-3969-e053-3a05fe0a2c94 2
null, file e309ade0-2863-3969-e053-3a05fe0a2c94 2
Progressive Motor Cortex Functional Reorganization Following 6-Hydroxydopamine Lesioning in Rats, file e309ade0-32cf-3969-e053-3a05fe0a2c94 2
null, file e309ade0-3f39-3969-e053-3a05fe0a2c94 2
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111, file e309ade0-4198-3969-e053-3a05fe0a2c94 2
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity, file e309ade2-7421-3969-e053-3a05fe0a2c94 2
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease, file e309ade2-a773-3969-e053-3a05fe0a2c94 2
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease, file e309ade3-70d7-3969-e053-3a05fe0a2c94 2
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease, file e309ade3-db81-3969-e053-3a05fe0a2c94 2
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease, file e309ade3-f75e-3969-e053-3a05fe0a2c94 2
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice, file e309ade3-fd2a-3969-e053-3a05fe0a2c94 2
Modeling Parkinson's disease in LRRK2 mice: Focus on synaptic dysfunction and the autophagylysosomal pathway, file e309ade5-a0c9-3969-e053-3a05fe0a2c94 2
L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter, file a971c687-0aa0-4ec1-9f60-aaeaffd12cbf 1
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior, file e309ade0-22e5-3969-e053-3a05fe0a2c94 1
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor, file e309ade0-246b-3969-e053-3a05fe0a2c94 1
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease, file e309ade0-2f55-3969-e053-3a05fe0a2c94 1
Loss of cortical GABA terminals in Unverricht–Lundborg disease, file e309ade0-3641-3969-e053-3a05fe0a2c94 1
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor, file e309ade0-38c8-3969-e053-3a05fe0a2c94 1
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease, file e309ade0-3b05-3969-e053-3a05fe0a2c94 1
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum, file e309ade0-460a-3969-e053-3a05fe0a2c94 1
Stimulation of Delta Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism, file e309ade0-460b-3969-e053-3a05fe0a2c94 1
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats, file e309ade0-4ac5-3969-e053-3a05fe0a2c94 1
Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias, file e309ade0-4d86-3969-e053-3a05fe0a2c94 1
null, file e309ade0-b853-3969-e053-3a05fe0a2c94 1
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia, file e309ade1-07cf-3969-e053-3a05fe0a2c94 1
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism, file e309ade1-1dfb-3969-e053-3a05fe0a2c94 1
Parkinson's disease: no NOP, new hope, file e309ade1-37c3-3969-e053-3a05fe0a2c94 1
NOP receptor ligands and Parkinson’s disease, file e309ade2-5f19-3969-e053-3a05fe0a2c94 1
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease, file e309ade3-707a-3969-e053-3a05fe0a2c94 1
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology, file e309ade5-715e-3969-e053-3a05fe0a2c94 1
Totale 2.195
Categoria #
all - tutte 9.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1
Totale 9.019


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 0 0 1 2 0 1 0 0 0
2020/2021144 0 0 0 0 0 0 0 3 35 40 44 22
2021/2022445 7 18 21 25 47 23 36 31 26 37 120 54
2022/2023588 23 40 112 77 49 54 37 31 42 40 58 25
2023/2024998 38 51 56 55 105 80 149 79 69 95 172 49
Totale 2.195